What is BioKey?
BioKey operates as a sophisticated contract development and manufacturing organization (CDMO), bridging the gap between early-phase product development and clinical supply manufacturing. The company distinguishes itself through the application of proprietary oral controlled release technologies, which are instrumental in the creation of both specialty generic and branded products. By maintaining cGMP-certified facilities, BioKey ensures that its production processes meet the rigorous quality standards required by the pharmaceutical and nutraceutical sectors. Their integrated service model allows clients to streamline the path from laboratory research to commercial-scale production, positioning BioKey as a critical partner in the life sciences supply chain.
How much funding has BioKey raised?
BioKey has raised a total of $132K across 1 funding round:
Debt
$132K
Debt (2021): $132K with participation from PPP
Key Investors in BioKey
PPP
Public-Private Partnership
What's next for BioKey?
With the infusion of this recent capital, BioKey is well-positioned to scale its operational capacity and further refine its proprietary delivery platforms. The company is expected to leverage these resources to expand its analytical service offerings and potentially increase its footprint in the specialty generic market. As the firm transitions through this late-stage growth phase, the focus will likely shift toward optimizing production efficiencies and securing long-term partnerships with global pharmaceutical entities. This strategic deployment of funds will be essential for maintaining a competitive edge in the highly regulated CDMO landscape, ensuring that BioKey remains at the forefront of oral drug delivery innovation.
See full BioKey company page
